Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
- Conditions
- Castration-resistant prostate cancer
- Registration Number
- NL-OMON20629
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Main inclusion criteria:
1. Age 50 or older.
Exclusion Criteria
Main exclusion criteria:
1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy of 18F-FDHT PET/CT as a predictor of treatment response
- Secondary Outcome Measures
Name Time Method Comparison of 'treatment response and clinical survival endpoints' versus 'no treatment response and clinical survival endpoints'